Conditions: Hepatitis C
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 58
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.

Detailed description:
Treatment, Parallel Assignment, Open Label, Non-Randomized, Single Dose Adaptive Design, Pharmacokinetics Study

Arms:
arm 1: Daclatasvir 60 mg tablet by mouth single dose on Day 1 arm 2: Daclatasvir 60 mg tablet by mouth single dose on Day 1 arm 3: Daclatasvir 60 mg tablet by mouth single dose on Day 1 arm 4: Daclatasvir 60 mg tablet by mouth single dose on Day 1

Interventions: intervention 1: Daclatasvir
Intervention descriptions: intervention 1: None

Protocol document: